Last reviewed · How we verify
Carvedilol 25 mg
At a glance
| Generic name | Carvedilol 25 mg |
|---|---|
| Also known as | Coreg |
| Sponsor | Yale University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Dizziness
- Nasopharyngitis
- Dyspepsia
- Chest pain
- Chest discomfort
- Pollakiuria
- Ischaemia
- Cerebral infarction
- Migraine
- Abdominal discomfort
- Constipation
Key clinical trials
- KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism (NA)
- Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136) (PHASE2)
- Carvedilol vs. Propranolol for Preventing Rebleeding After Endoscopic Treatment of Cirrhotic Varices (PHASE4)
- CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes (PHASE3)
- DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis (PHASE4)
- Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure (PHASE2)
- Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure (PHASE4)
- Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carvedilol 25 mg CI brief — competitive landscape report
- Carvedilol 25 mg updates RSS · CI watch RSS
- Yale University portfolio CI